AbbVie

AbbVie, Galapagos to co-develop cystic fibrosis therapies

Wednesday, September 25, 2013 12:24 PM

Galapagos and AbbVie have entered into a global alliance to discover, develop and commercialize novel potentiator and combination therapies in cystic fibrosis (CF), an inherited chronic disease that affects 70,000 people worldwide.

More... »

Ablynx, AbbVie enter global license agreement for inflammatory diseases

Monday, September 23, 2013 01:37 PM

Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies, and AbbVie have entered into a global license agreement to develop and commercialize the anti-IL-6R Nanobody, ALX-0061, to treat inflammatory diseases.

More... »

Verified Clinical Trials partners with SAFE-BioPharma

Friday, July 26, 2013 09:00 AM

Verified Clinical Trials, whose technology helps eliminate multiple enrollments by clinical trial volunteers and provides Medicare Secondary Payer Law compliance strategies, will offer its services with SAFE-BioPharma, a global digital identity management and signature standard used by many of the world’s largest biopharmaceutical companies. The company also has joined the SAFE-BioPharma Vendor Partner program, providing it with direct access to decision-makers in SAFE-BioPharma’s member companies.

More... »

AbbVie and Galapagos extend GLPG0634 collaboration

Monday, June 10, 2013 11:39 AM

Galapagos, which specialized in novel modes-of-action, and AbbVie have extended their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a phase II program in Crohn's, designed to facilitate rapid progression into phase III.  Upon successful completion of the study, expected in the second quarter of 2015, AbbVie will pay Galapagos $50 million. 

More... »

AbbVie, Alvine collaborate on investigational oral therapy

Monday, June 10, 2013 11:28 AM

AbbVie and Alvine Pharmaceuticals, a developer of celiac disease therapeutics, have entered a global collaboration to develop a novel oral treatment for patients with celiac disease, currently in phase II development.

More... »

Biogen Idec, WPI to develop programs for BETC

Friday, May 31, 2013 10:50 AM

Global biotechnology company Biogen Idec has signed a collaboration agreement with Worcester Polytechnic Institute (WPI) to develop and deliver programs at the university’s Biomanufacturing Education and Training Center (BETC) of Worcester, Mass.

More... »

Abbott completes separation of research-based pharmaceuticals business

Wednesday, January 2, 2013 02:09 PM

Global healthcare company Abbott Laboratories has completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. AbbVie began trading independently on the New York Stock Exchange on Jan. 2, 2013, under the symbol "ABBV."

More... »

Abbott board approves separation of AbbVie

Thursday, November 29, 2012 01:46 PM

The board of directors of Illinois-based Abbott has approved the separation of its research-based pharmaceuticals business, to be known as AbbVie, and declared a special dividend distribution of all outstanding shares of AbbVie common stock.

More... »

Abbott selects “AbbVie” as new name for future pharma company

Thursday, March 22, 2012 06:30 AM

Abbott has dubbed its new, independent research-based pharmaceutical company AbbVie (pronounced Abb-vee), which it will launch by the end of 2012.

More... »